Search results | pdl biopharma


Partnering Agreements with PDL BioPharma

The Partnering Agreements with PDL BioPharma report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.


PDL Biopharma: Capitalizing on the humanization of monoclonal antibodies

PDL Biopharma based in Nevada manages patents associated with its humanized monoclonal antibodies technology.   

PDL Biopharma : Partnering and Financing activity 2009-2014

PDL Biopharma, formerly known as Protein Design labs, is headquartered in Nevada.

PDL BioPharma: Company profile

Biopharma features strongly in 2013 world’s most innovative companies list

Partnering activity of the biopharma companies in Forbes Most Innovative Company list reviewed

Current Agreements Deal Analysis Update : March 2014

This month we provide you with an overview of deal analysis life science deal making activity, covering partnering, M&A and financing in February 2014

Abbott strengthens pipeline through acquisition of Facet for $722m

Abbott laboratories strengthened its pharmaceutical pipeline in immunology and oncology through the acquisition of Facet Biotech for $722 million.


Sorry, your search returned no results.


PDL BioPharma, in new licensing agreement with Eli Lilly

Non-exclusive license agreement with Eli Lilly under PDL’s Queen et al patents with respect to teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules. Teplizumab is currently being studied by Lilly and its partner MacroGenics for the treatment of individuals with newly-diagnosed type 1 diabetes mellitus. No other details more »

PDL gives debt financing for $75 million to Paradigm Spine

PDL BioPharma and Paradigm Spine have entered into a credit agreement whereby PDL will provide Paradigm with up to $75 million of secured debt financing.

PDL to raise $250 million in convertible senior notes financing

PDL BioPharma announced $250 million aggregate principal amount of new convertible senior notes due February 1, 2018.

PDL pours in $70 million in debt financing to Durata Therapeutics

PDL will provide Durata with up to $70 million of debt financing with a five year term.

PDL life science deals with Avinger for $40 million loan financing

Medical device company, Avinger, life science deals with PDL BioPharma for a structured financing and royalty transaction in which PDL will provide Avinger with up to $40 million of mezzanine financing. 

Direct Flow Medical nets $32 million

Direct Flow Medical announced the closing of a new round of financing for the company totaling $32 million

LENSAR in $87 million debt and equity financing

LENSAR announced the closing of $27 million in private equity financing and up to $60 million in debt financing

Merus Labs announces completion of debt financing

Merus Labs International has refinanced its debt obligation previously provided by PDL BioPharma which had an outstanding amount owing of US$39.5 million, by closing on two new debt instruments: a C$30 million senior credit facility with the Royal Bank of Canada and the Bank of Montreal, and a C$10 million convertible note debenture with a more »